Reistone Biopharma Appoints Andrew Chen as Vice President, Head of Finance

 


Reistone Biopharma Company Limited (Reistone Biopharma) recently announced the appointment of Andrew Chen as Vice President, Head of Finance. Andrew will be based in Shanghai and report to Min Irwin, CEO.
Andrew received his master's degree from Fudan-MIT International MBA Program in 2006. In 1999, he earned a dual bachelor’s degree from Shanghai Jiaotong University, majoring in Electrical Engineering and Industrial Engineering, respectively.
Andrew has 20 years working experience in power supply, semi-conductor, and pharmaceutical industry.
Prior to joining Reistone Biopharma, Andrew held several positions of increasing responsibilities in Intel Corporation and Wuxi AppTec Group. He worked for more than 13 years in Wuxi AppTec and its subsidiaries.
Since 2009, Andrew had served as Chief Financial Officer of STA Pharmaceutical, the CDMO business unit of Wuxi AppTec Group, managed a financial team of more than 30 staff members, led and executed several key strategies during the growth of STA Pharmaceutical. With his leadership and support, STA Pharmaceutical had grown from several hundreds of employees to more than six thousand. Andrew also led the listing of STA Pharma on the National Equities Exchange and Quotations (NEEQ) in 2015, and participated the due-listing of Wuxi AppTec Group in Shanghai and Hong Kong Security Exchanges in 2018.
"Andrew Chen will be responsible for Reistone Biopharma's financial management, accounting, financial analysis, and support the company's strategic decision making, and daily operations as well", Dr. Min Irwin noted, "We are confident with the joining of Andrew. Reistone Biopharma will benefit from his rich experience, strong leadership and sharp business sense. His team and Reistone Biopharma will definitely achieve greater successes."

About Reistone Biopharma
Reistone Biopharma Company Limited is a clinical stage bio-pharmaceutical company with pipelines in immuno-inflammatory therapies focused on developing novel medicines aimed at treating autoimmune and inflammatory diseases of high unmet needs. Founded in January 2018, and headquartered in Zhangjiang, Shanghai, Reistone Biopharma has nearly 140 employees in China and the United States by November 2020. Currently, Reistone Biopharma has 7 phase II clinical trials and 2 phase I clinical trials involving 4 novel products globally. Its new drug research and development laboratory located in Zhangjiang High-Tech core area of Pudong district is under construction and is scheduled to start operation in the middle of year 2021. Several preclinical projects are now in different researching and development stages.

For more information, please visit www.ReistoneBio.com


Date of issue:2020-12-02 20:30
Share to:
Read more articles